Prevalence of High-risk Human Papillomavirus (HPV) Infection Among Thai Women in Lopburi, Ang Thong and Phetchabun Provinces
Keywords:
Prevalence of high risk human papillomavirus (HPV) infection, High risk human Papilloma virus (HR-HPV), Liquid-based cytology (LBC)Abstract
Background: Most cases of cervical cancer are caused by infection with high risk human papillomavirus (HR-HPV) types. Objective: To study the prevalence of HR-HPV infection in Thai women in Lopburi, Ang Thong and Phetchabun Provinces. Method: It is a cross-sectional study. The data was collected from Laboratory Information system (LIS) to study in Thai women aged 30-60 years old during October 2021 to March 2022. Descriptive statistics, chi-square test and independent t-test were used to analyze. Results: 1,033 out of 18,202 women were infected with HR-HPV (5.7%). Most of those infected were 41-50 years old. Age range was significantly related to HR-HPV infection (p-value < .001). The prevalence of the HR-HPV infection in Ang Thong, Lopburi and Phetchabun was 7.5%, 6.6%, and 4.7%, respectively. The proportion of other HR HPV, 16, 18 and 16 with other HR-HPV was 71.9%, 14.9%, 5.5%, and 5.4% respectively. Among cases infected with other HR-HPV, 734 cases had abnormal results from LBC (12.1%). Those with abnormal results from Liquid-based cytology (LBC) have an average age of 457.45 years old. Age range was significantly related to HR-HPV infection (p-value < .01). The abnormal results from LBC in Lopburi, Phetchabun and Ang Thong was 16.3%, 11.6%, and 7.3%, respectively. Conclusion: The highest prevalence of HR-HPV infection was in Ang Thong province, followed by Lopburi and Pethchabun. It was found that the age range of 30-40 years old had the highest infection. Other HR-HPV had the highest prevalence of infection, followed by the infection from HPV types 16 and 18. Lopburi Province had the most cases with abnormal results from LBC followed by Phetchabun and Ang Thong. This study could be useful for cervical cancer surveillance programs, the development of cervical cancer screening system, and guidelines on cervical cancer vaccine management.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians 2018;68:394-424.
Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. Human Papillomavirus and related diseases report October 2021. [internet] 2023 [cite 2023]. Available from: https://hpvcentre. net/statistics/reports/XWX.pdf
Ferris DG, Brown DR, Giuliano AR, Myer E, Joura EA, Garland SM, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res 2020;10:10020.
Boonthum N, Suthutvoravut S. Prevalence, types, and factors of HPV infection among women with abnormal cervical cytology screening at Ramathibodi Hospital. Rama Med J 2021;44(3):12-9.
Beyazit F, Sılan F, Gencer M, Aydin B, Paksoy B, Unsal MA, et al. The prevelance of human papillomavirus (HPV) genotypes detected by PCR in women with normal and abnormal cervico-vaginal cytology. Ginekol Pol 2018;89(2):62-7.
Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine 2018;36(32 Pt A):4783-91.
Zeferino L, Bastos J, Vale D, Zanine R, Melo Y, Primo W, et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet 2018;40(6):360-8.
Phetphichai S, KlyKleung N, Porta A, Bunkhong A, Kanyaboon P. The prevalence of high-risk HPV type among Thai women in Phichit, Uthai Thani, Chainat and Kamphaeng Phet provinces. Bull Dept Med Sci 2021;31;63(4):766-81.
Tangsiriwatthan T, Pholampaisathit S, Chainual A, Boonsom K, Vittayanan S, Thichak S, et al. Prevalence of human papillomavirus (HPV) infection and genotypes in Thai women with normal cervical cytology. Bull Dept Med Sci 2019;61(2):73-85.
Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infect Agents Cancer 2018;13:6.
Kesheh M Mobini, Keyvani H. The prevalence of HPV genotypes in Iranian population: an update. Iran J Pathol 2019;14(3): 197-205.
Luo LP, He P, Liu QT, Jiang YH, Zhang YN, Li QZ, et al. Prevalence and genotype distribution of HPV infection among 214,715 women from Southern China, 2012-2018: baseline measures prior to mass HPV vaccination. BMC Infect Dis 2021;21(1):328.
Nakrukamphonphatn S, Suwannakoot N, Natason A. Predicting factors of primary prevention of cervical cancer among couples. RHPC9J 2022;16(2):469-83.
Vaisopha N. Prevalence of cervical cancer of women who screened cervical cancer between 2015 and 2019 in KhonKaen hospital. J Res Health Inno Dev 2021;2(1):113-22.
Laohutanon P. Screening guidelines dianose and cervical cancer. The National Cancer Institute of Department of Medical Service of Ministry of Ministry of Pubic Health 2018:7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
